OBREXA 10/160 mg price in UAE

Overview

Welcome to Dwaey, specifically on OBREXA 10/160 mg Tablet/ Film coated page.
This medicine contains an important and useful components, as it consists of Amlodipine,Valsartan.
OBREXA 10/160 mg is available in the market in concentration 10 mg/tablet, 160 mg/tablet and in the form of Tablet/ Film coated.

SEVANA PHARMACUTICALS is the producer of OBREXA 10/160 mg and it is imported from UAE, The most popular alternatives of OBREXA 10/160 mg are listed downward .

Mode Of Action

Amlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage-sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients w/ vasospastic angina. Valsartan, an angiotensin II type 1 (AT1) receptor antagonist, produces its BP lowering effects by inhibiting angiotensin II-induced vasoconstriction, aldosterone release and renal reabsorption of Na.

Indication

Hypertension

Precaution

Impaired liver or renal function, CHF, sick-sinus syndrome, severe ventricular dysfunction, hypertrophic cardiomyopathy, severe aortic stenosis. Caution when used in patients with idiopathic hypertrophic subaortic stenosis. Elderly, children. During the second and third trimesters of pregnancy, these drugs have been associated with fetal injury that includes hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Discontinue as soon as possible when pregnancy is detected; affects renin-angiotensin system causing oligohydramnios, which may result in fetal injury and/or death Lactation: discontinue drug or do not nurse

Side Effects

>10% Headache
Increased BUN (6-17%) 1-10% Peripheral edema (5-8%)
Anxiety (3%)
Nasopharyngitis (4%)
Increased potassium (3%)
Upper respiratory infection (3%)
Dizziness (2%)
Somnolence (3%)
Diarrhea (3%)
Nausea (3%)
Abdominal pain (3%)
Cough (2%) <1% Orthostatic hypotension
Syncope
Visual disturbance
Tinnitus
Exanthema Potentially Fatal: Hypotension
bradycardia
conductive system delay and CCF.

Contra indication

Known hypersensitivity to dihydropyridines.

Pregnancy and lactation

Pregnancy category: C+D

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Pregnancy Category: C (1st trimester); D (2nd & 3rd trimesters).

Interaction

Amlodipine : Plasma concentrations may be elevated w/ CYP3A4 inhibitors (e.g. azole antifungals, ritonavir). Concomitant therapy w/ simvastatin may increase risk of myopathy including rhabdomyolysis. May increase ciclosporin plasma levels and conivaptan. Valsartan : May antagonise hypotensive effects and increase the risk of renal impairment w/ NSAIDs. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes. Potentially Fatal: Increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure) when used w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).

UAD 92

Purchase Now(Soon) Explore Other Medicines